

News Releases

All Years

Search

Go

[Advanced Search](#)

FEB 28, 2024

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

JAN 23, 2024

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to \$2.2B

NOV 9, 2023

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

NOV 2, 2023

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

OCT 18, 2023

Inhibrx Announces Participation in Upcoming Scientific Conferences

AUG 29, 2023

Inhibrx Announces \$200 Million Private Placement Financing

AUG 7, 2023

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Recent Corporate Highlights

MAY 30, 2023

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

MAY 8, 2023

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

MAR 6, 2023

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

JAN 4, 2023

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

NOV 18, 2022

Inhibrx Announces Participation in Upcoming Investor Conference

NOV 16, 2022

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

NOV 7, 2022

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

OCT 20, 2022

Inhibrx Announces Participation in Upcoming Scientific

Conferences

AUG 15, 2022

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

AUG 8, 2022

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

JUN 30, 2022

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional \$60 Million from Oxford Finance

MAY 19, 2022

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

MAY 12, 2022

Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

MAY 9, 2022

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

MAR 24, 2022

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

FEB 28, 2022

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

FEB 22, 2022

Inhibrx Announces Amended Loan Agreement with Oxford

JAN 4, 2022

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

Show per page

[«](#) [1](#) [2](#) [3](#) [4](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?l=25&o=25>